OWLT · Owlet, Inc.
The latest filing states the doubt was alleviated.
“In accordance with ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the unaudited condensed consolidated financial statements included in this quarterly report on Form 10-Q are issued.”View the 10-Q filed Aug 14, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jul 10, 2023; bars on opposite sides are not compared.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 11, 2026TL;DR. Owlet delivered record Q2 revenue and subscription growth, and raised full-year gross-margin and adjusted-EBITDA guidance largely to reflect a one-time tariff refund. It retained full-year revenue guidance while cautioning that Q3 revenue will decline sequentially and year over year amid aggressive discounting and tougher comparisons.
- + Q2 revenue reached a record $33.9 million, up 29.9% year over year.
- + Subscription revenue rose to a record $3.2 million, up $2.4 million year over year.
- + Underlying Q2 gross margin expanded to 54.0%, up 270 basis points year over year.
- + Full-year gross-margin guidance increased to 53%–55% from 50%–52%.
- + Full-year adjusted-EBITDA guidance increased to $10.75–$12.75 million from $7–$9 million.
- − Q3 revenue is expected to decline both sequentially and year over year.
- − Aggressive competitor discounting and cautious consumer spending are pressuring near-term sales.
- − Prime Day units sold declined 8% versus the prior-year event.
- − Operating expenses increased to $20.1 million from $15.1 million.
- − Full-year guidance improvements were driven only by the one-time tariff refund, leaving underlying expectations essentially unchanged.
- − Average subscriber use remains about 12 months, below the company's at-least-two-year objective.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OWLT
this stock
Owlet, Inc.
|
$137.05M | -71.0% | +37.1% | — | 2.0% |
|
ABT
Abbott Laboratories
|
$178.08B | -18.6% | +5.7% | 28.6 | 1.3% |
|
MDT
Medtronic plc
|
$116.35B | -5.3% | +8.4% | 22.4 | 0.9% |
|
SYK
Stryker Corp
|
$105.70B | -21.6% | +11.2% | 28.6 | 2.0% |
|
BSX
Boston Scientific Corp
|
$62.29B | -54.9% | +12.5% | 17.4 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jul 10, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OWLT | -6.8% | -25.2% | -8.8% | -5.8% | -71.0% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -5.6% | -23.5% | -26.6% | -5.5% | -83.1% |